Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?
Currently, therapeutic drug monitoring (TDM) of antiretroviral therapy (ART) is not performed in the United States as part of routine clinical care of an HIV-infected adolescent patient. TDM is recommended to rule out subtherapeutic drug concentrations and to differentiate among malabsorption, drug interactions, poor adherence, or increased drug metabolism or clearance as possible causes of decreased drug exposure. The use of TDM is also considered to assist in finding the optimal dose of a drug in patients whose virus has shown reduced susceptibility to that drug. The dosing of antiretroviral (ARV) drugs in adolescent patients with HIV infection depends on the chronologic age, weight, height, and the stage of sexual maturation. As a result of the limited data on the pharmacokinetics of ART during puberty, the transition of a dosing regimen from higher pediatric (weight and surface-based) to adult (fixed) range is not well defined. Developmental pharmacokinetic differences contribute to high variability in pediatric and adolescent patients and an increased frequency of suboptimal ARV exposure as compared to in adults. Individualized, concentration-targeted optimal dosing of ARV medications can be beneficial to patients for whom only limited dosing guidelines are available. This article describes three cases of the application of TDM in treatment-experienced adolescent patients whose ART was optimized using ARV TDM. TDM of ARV drugs is useful in managing the pharmacotherapy of HIV in adolescent patients and is well received by the adolescent patients with HIV and their families. Among others, the benefits of TDM provide evidence for adherence interventions and create grounds for enhanced education of the adolescent patient and involved adult caregivers about ART. Finally, TDM in adolescents provides valuable information about the clinical pharmacology of ART during puberty.
Rakhmanina
Natella Y
NY
Division of Infectious Disease, Children's National Medical Center, Washington, DC, USA. nrakhman@cnmc.org
van den Anker
John N
JN
Soldin
Steven J
SJ
van Schaik
Ron H
RH
Mordwinkin
Nick
N
Neely
Michael N
MN
D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016903:Drug Monitoring; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D055815:Young Adult
D019380:Anti-HIV Agents
HIV Med. 2009 Sep;10(8):520-3
19486190
J Clin Pharmacol. 2008 Nov;48(11):1282-8
18779377
Pharmacotherapy. 2008 Jun;28(6):782-7
18503405
AIDS. 2004 Dec 3;18(18):2391-400
15622315
Drugs. 2005;65(3):413-32
15669881
Expert Opin Pharmacother. 2009 Dec;10(17):2773-8
19929700
Clin Biochem. 2002 Mar;35(2):99-103
11983343
Clin Pharmacol Ther. 2007 Apr;81(4):557-66
17235330
Clin Infect Dis. 2006 Apr 15;42(8):1189-96
16575741
Antimicrob Agents Chemother. 2002 Mar;46(3):884-6
11850280
Pediatrics. 2007 Jun;119(6):e1371-83
17533177
AIDS Care. 2004 Apr;16(3):323-38
15203426
Ther Drug Monit. 2003 Oct;25(5):541-3
14508375
Ther Drug Monit. 2005 Aug;27(4):412-6
16044095
Clin Pharmacokinet. 2008;47(6):351-71
18479171
J Pharmacol Exp Ther. 2006 Jul;318(1):345-51
16611850
Eur J Clin Pharmacol. 2006 Apr;62(4):267-75
16506047
Pediatrics. 2004 Nov;114(5):e591-7
15520091
Clin Infect Dis. 2007 Nov 1;45(9):1230-7
17918089
Br J Clin Pharmacol. 2009 Apr;67(4):427-36
19371316
Clin Pharmacol Ther. 2008 Dec;84(6):734-40
18830226
AIDS Care. 2001 Feb;13(1):27-40
11177463
Antimicrob Agents Chemother. 2009 Jul;53(7):2791-8
19433561
Pharmacogenomics. 2007 Jun;8(6):547-58
17559344
AIDS Behav. 2007 Mar;11(2):161-73
16804749
AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):825-34
12201904
Clin Infect Dis. 2007 Nov 15;45(10):e128-30
17968817
Antivir Ther. 2009;14(3):315-20
19474465
Drugs. 2005;65(16):2309-36
16266202
Antivir Ther. 2009;14(1):75-83
19320239
Br J Clin Pharmacol. 1999 Nov;48(5):712-5
10594473
J Adolesc Health. 2002 Mar;30(3):161-8
11869922
Pharmacotherapy. 2001 Apr;21(4):424-30
11310515
Clin Pharmacokinet. 2008;47(10):681-92
18783298
AIDS. 2007 Oct 18;21(16):2191-9
18090046
Eur J Clin Pharmacol. 2008 Apr;64(4):357-65
18057928
Pediatrics. 2002 Apr;109(4):e61
11927734
Br J Clin Pharmacol. 2005 Oct;60(4):378-89
16187970
Pediatr Infect Dis J. 2002 Aug;21(8):743-7
12192162
Clin Pharmacol Ther. 2009 May;85(5):485-94
19225447
Antimicrob Agents Chemother. 2009 Jun;53(6):2532-8
19258274
Ther Drug Monit. 2007 Feb;29(1):110-7
17304158
AIDS Patient Care STDS. 2009 Mar;23(3):185-94
19866536
J Pharmacol Exp Ther. 2004 Oct;311(1):34-43
15190123
J Antimicrob Chemother. 2008 Apr;61(4):914-8
18281305
J Clin Pharmacol. 2008 Sep;48(9):1081-91
18635757
Drug Metab Dispos. 1999 Nov;27(11):1319-33
10534318
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):240-5
19593159
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5
17356468
J Pharmacol Exp Ther. 2003 Jul;306(1):287-300
12676886
Arch Dis Child. 2009 Dec;94(12):970-3
19723637
Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13
19635964
Ther Drug Monit. 2004 Apr;26(2):122-6
15228151
AIDS. 2002 Mar;16 Suppl 1:S5-37
12035820